HEM.V - Hemostemix Inc.

TSXV - TSXV Delayed Price. Currency in CAD

Hemostemix Inc.

2150, 300 – 5 Avenue SW
Calgary, AB T2P 3C4

Full Time Employees

Key Executives

NameTitlePayExercisedYear Born
Mr. Kyle MakofkaChief Exec. Officer105.76kN/AN/A
Dr. Alan J. Jacobs M.D., Ph.D.Pres & Chief Medical OfficerN/AN/AN/A
Ms. Kristin Gulka CPA, CAChief Financial OfficerN/AN/AN/A
Ms. Eilat BainDirector of OperationsN/AN/AN/A
Amounts are as of December 31, 2017 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in CAD.


Hemostemix Inc., a clinical-stage biotechnology company, develops, manufactures, and commercializes blood-derived cell therapies for medical conditions in Canada. It develops cell therapy products from the patient's own blood, a relatively non-invasive source of therapeutic cells. The company's lead product is ACP-01, which is in Phase II clinical trial for the treatment of critical limb ischemia. It is also developing various types of cells products, such as synergetic cell precursors, myocardial cell precursors, and neural cell precursors. Hemostemix Inc. is headquartered in Calgary, Canada.

Corporate Governance

Hemostemix Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.